Trials / Completed
CompletedNCT05883306
Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans
A Clinical Trial to Assess Absorption, Metabolism and Excretion of [14C]-LXI-15028 in Chinese Healthy Male Subjects - Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To assess absorption, metabolism and excretion of \[14C\]-LXI-15028 in Chinese healthy male Subjects following a single oral dose of \[14C\]LXI-15028 suspension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]LXI-15028 | \[14C\]LXI-15028 |
Timeline
- Start date
- 2022-06-30
- Primary completion
- 2022-07-21
- Completion
- 2022-12-23
- First posted
- 2023-05-31
- Last updated
- 2023-05-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05883306. Inclusion in this directory is not an endorsement.